Clinical Trial Details

Overview

Research Study Summary

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Purpose

Inflammatory bowel diseases, including ulcerative colitis, are chronic relapsing disorders characterized by destructive inflammation and epithelial injury in the gastrointestinal tract. This study will evaluate the efficacy of intravenous (IV) ustekinumab in inducing clinical remission in subjects with moderately to severely active ulcerative colitis.

To Learn more

CW ID: 214279
Date Last Changed: May 17, 2016

Clinical Trial Snapshot

Gender
Both Male and Female
Age
18 and up
Overall Status
Recruiting
Lead Sponsor
Janssen
Facility Type
N/A

Eligibility

Inclusion Criteria:
  • Defined moderately to severely active ulcerative colitis, as defined by a Mayo score of 6 to 12.
  • Must not be at imminent risk of colectomy

Contact

Rachel Karlnoski
University of South Florida- South Tampa Center For Advanced Healthcare
1 Tampa General Circle
Tampa, FL 33606
Phone: 813-844-4133

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.